A population-based case-control teratologic study of ampicillin treatment during pregnancy

Czeizel, Andr̀ew E.; Rockenbauer, Magda; Sørensen, Henrik Toft; Olsen, Jørn

doi:10.1067/mob.2001.113907

Cited by 42 publications

(32 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…43,44 Their safety profile has been confirmed in multiple studies. 31,[44][45][46][47] These b-lactams include penicillin G, ampicillin, and amoxicillin. Although resistance is common, these drugs are considered first-line therapy for susceptible bacteria, especially for GBS.…”

Section: Penicillinsmentioning

confidence: 99%

Urinary Tract Infection and Bacteriuria in Pregnancy

Glaser

Schaeffer

2015

Urologic Clinics of North America

153

115

View full text Add to dashboard Cite

Section: Penicillinsmentioning

confidence: 99%

Urinary Tract Infection and Bacteriuria in Pregnancy

Glaser

Schaeffer

2015

Urologic Clinics of North America

153

115

View full text Add to dashboard Cite

“…89 Finally, in a large population-based (Hungarian) case-control study of maternal ampicillin use in the second or third month of pregnancy, no association was found among 4468 cases with cardiovascular malformations. 90 Multiple large studies have shown no association between the use of penicillin (FDA category B) and an increased risk of congenital anomalies in general. [91][92][93][94] One Danish population-based record linkage study that examined the frequency of congenital heart defects in mothers given penicillin during the first trimester showed it to be no higher than expected.…”

Section: Vitamin a Cogeners/retinoidsmentioning

confidence: 99%

Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge

Jenkins¹,

Correa²,

Feinstein³

et al. 2007

Circulation

712

336

View full text Add to dashboard Cite

Abstract-Prevention of congenital cardiovascular defects has been hampered by a lack of information about modifiable risk factors for abnormalities in cardiac development. Over the past decade, there have been major breakthroughs in the understanding of inherited causes of congenital heart disease, including the identification of specific genetic abnormalities for some types of malformations. Although relatively less information has been available on noninherited modifiable factors that may have an adverse effect on the fetal heart, there is a growing body of epidemiological literature on this topic. This statement summarizes the currently available literature on potential fetal exposures that might alter risk for cardiovascular defects. Information is summarized for periconceptional multivitamin or folic acid intake, which may reduce the risk of cardiac disease in the fetus, and for additional types of potential exposures that may increase the risk, including maternal illnesses, maternal therapeutic and nontherapeutic drug exposures, environmental exposures, and paternal exposures. Information is highlighted regarding definitive risk factors such as maternal rubella; phenylketonuria; pregestational diabetes; exposure to thalidomide, vitamin A cogeners, or retinoids; and indomethacin tocolysis. Caveats regarding interpretation of possible exposure-outcome relationships from case-control studies are given because this type of study has provided most of the available information. Guidelines for prospective parents that could reduce the likelihood that their child will have a major cardiac malformation are given. Issues related to pregnancy monitoring are discussed. Knowledge gaps and future sources of new information on risk factors are described.

show abstract

“…Thus the treatment of pregnant women with most frequently used drugs for VV-BV during the study pregnancy did also not associate with a higher risk for any CA. This finding is an important argument against the teratogenic effect of metronidazole [27], clotrimazole [28], ampicillin [29], penamecillin [30] and nitrofurantoin [31]. On the other hand these drugs can reduce the maternal VV-BV related preterm births in their babies;therefore their use is important during early pregnancy as well.…”

Section: Discussionmentioning

confidence: 99%

No association between vulvovaginitis-bacterial vaginosis, related drug treatments of pregnant women, and congenital abnormalities in their offspring — A population-based case-control study

et al. 2008

View full text Add to dashboard Cite

AbstractThe possible association between prospectively and medically recorded vulvovaginitis-bacterial vaginosis (VV-BV) and different congenital abnormalities (CA) has not been studied. The data set of the population-based Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 were evaluated, i.e. 22,843 pregnant women who had newborns or fetuses with congenital abnormality (cases) and 38,151 pregnant women who delivered newborn babies without any congenital abnormality (controls). The main outcome measures were different congenital abnormalities. Of 22,843 cases with CA, 1,536 (6.7%) had mothers with VV-BV, while of 38,151 matched controls without CA, 2,698 (7.1%) had mothers with VV-BV in the second and/or third gestational month of pregnancy. Nearly all pregnant women with VV-BV were treated during pregnancy, but a higher risk for the total group of CAs (adjusted POR with 95% CI: 0.95, 0.89–1.02) or any CA group was not found. In addition, the risk for total CAs was significantly lower in cases born to mothers with VV-BV and appropriate treatment than born to mothers with VV-BV but without treatment. Thus maternal VV-BV needs treatment during pregnancy as well, because it helps reduce the rate of preterm birth without a risk for CAs.

show abstract

A population-based case-control teratologic study of ampicillin treatment during pregnancy

Cited by 42 publications

References 12 publications

Urinary Tract Infection and Bacteriuria in Pregnancy

Urinary Tract Infection and Bacteriuria in Pregnancy

Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge

No association between vulvovaginitis-bacterial vaginosis, related drug treatments of pregnant women, and congenital abnormalities in their offspring — A population-based case-control study

Contact Info

Product

Resources

About